MDT analyst scorecard · Medtronic
60 rating actions on MDT in the last 12 months. Of 56 price targets that resolved, 13 were reached while they stood, 42 were replaced by the same firm first, and 1 fell short at their deadline. Ratings: 68% Buy-type, 32% Hold-type, 0% Sell-type. Consensus target $105, 8% above the last close.
Checked through 2026-10-29 · last close $96.94 (2026-10-29). Rebuilt every morning.
What the Holds say: 19 Hold-type ratings on MDT in the last 12 months carried a median target +6% from the price on the day; 0% sat below it.
The 5 upgrades on MDT came after an average +4.0% move in the 30 days before them.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Needham | Buy | 2026-09-01 | $114 | 0 | 6 | 6 | — |
| Barclays | Equal-Weight | 2026-10-07 | $95 | 1 | 5 | 6 | 1 of 1 |
| Bernstein | Outperform | 2026-06-05 | $97 | 1 | 2 | 3 | 1 of 1 |
| Leerink Partners | Outperform | 2026-06-04 | $104 | 0 | 1 | 1 | 0 of 1 |
| William Blair | Outperform | 2026-01-06 | — | — | — | 0 | — |
| BTIG | Buy | 2026-10-12 | $99 | 1 | 1 | 2 | — |
| TD Cowen | Buy | 2026-09-30 | $110 | 0 | 2 | 2 | — |
| UBS | Buy | 2026-09-03 | $110 | 2 | 2 | 4 | — |
| Mizuho | Outperform | 2026-06-03 | $100 | 1 | 2 | 3 | 0 of 1 |
| Wells Fargo | Overweight | 2026-09-02 | $104 | 1 | 3 | 4 | 1 of 1 |
| RBC Capital | Outperform | 2026-09-02 | $118 | 0 | 2 | 2 | 1 of 1 |
| Evercore ISI Group | Outperform | 2026-07-06 | $105 | 0 | 3 | 3 | 0 of 1 |
| Truist Securities | Hold | 2026-09-02 | $99 | 3 | 4 | 7 | — |
| Baird | Neutral | 2026-09-02 | $100 | 1 | 3 | 4 | — |
| Goldman Sachs | Neutral | 2026-06-05 | $83 | 0 | 1 | 1 | — |
| JPMorgan | Neutral | 2026-02-18 | $100 | — | — | 0 | — |
| Bank of America | Buy | 2026-09-02 | $110 | — | — | 0 | — |
| Stifel | Hold | 2026-09-02 | $95 | 1 | 0 | 1 | — |
| Citigroup | Buy | 2026-04-07 | $110 | 0 | 4 | 4 | 0 of 1 |
| Argus Research | Buy | 2026-04-06 | $115 | 0 | 0 | 1 | 0 of 1 |
| Piper Sandler | Neutral | 2026-04-01 | $91 | 1 | 0 | 1 | — |
| Morgan Stanley | Overweight | 2025-11-19 | $117 | 0 | 1 | 1 | — |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor MDT carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | BTIG | Buy | maintained | $91.93 | $99 | running to 2027-10-12 | +1.1% |
| 2026-10-07 | Barclays | Equal-Weight | initiated | $85.51 | $95 | reached 2026-10-15 | -9.2% |
| 2026-09-30 | TD Cowen | Buy | reiterated | $86.29 | $110 | running to 2027-09-30 | -4.8% |
| 2026-09-03 | UBS | Buy | maintained | $93.10 | $110 | running to 2027-09-03 | +8.0% |
| 2026-09-02 | Truist Securities | Hold | reiterated | $92.18 | $99 | running to 2027-09-02 | +6.3% |
| 2026-09-02 | Wells Fargo | Overweight | maintained | $92.18 | $104 | running to 2027-09-02 | +6.3% |
| 2026-09-02 | RBC Capital | Outperform | reiterated | $92.18 | $118 | running to 2027-09-02 | +6.3% |
| 2026-09-02 | Bank of America | Buy | maintained | $92.18 | $110 | running to 2027-09-02 | +6.3% |
| 2026-09-02 | Stifel | Hold | maintained | $92.18 | $95 | within 5% of price when set | +6.3% |
| 2026-09-02 | Baird | Neutral | maintained | $92.18 | $100 | running to 2027-09-02 | +6.3% |
| 2026-09-01 | BTIG | Buy | maintained | $92.04 | $100 | replaced 2026-10-12, new $99 | +7.8% |
| 2026-09-01 | Needham | Buy | reiterated | $92.04 | $114 | running to 2027-09-01 | +7.8% |
| 2026-08-28 | TD Cowen | Buy | maintained | $91.23 | $110 | running to 2027-08-28 | +4.2% |
| 2026-08-27 | Needham | Buy | maintained | $89.97 | $114 | running to 2027-08-27 | +3.6% |
| 2026-08-18 | BTIG | Buy | reiterated | $92.09 | $91 | within 5% of price when set | +10.7% |
| 2026-07-28 | UBS | Neutral → Buy | upgrade | $86.88 | $100 | replaced 2026-09-03, new $110 | +7.3% |
| 2026-07-10 | TD Cowen | Buy | maintained | $83.87 | $100 | replaced 2026-08-28, new $110 | +4.5% |
| 2026-07-06 | Evercore ISI Group | Outperform | maintained | $83.06 | $105 | running to 2027-07-06 | +1.7% |
| 2026-06-17 | Needham | Buy | reiterated | $78.14 | $101 | replaced 2026-08-27, new $114 | +1.1% |
| 2026-06-05 | Goldman Sachs | Neutral | maintained | $81.67 | $83 | within 5% of price when set | +5.2% |
| 2026-06-05 | Bernstein | Outperform | maintained | $81.67 | $97 | running to 2027-06-05 | +5.2% |
| 2026-06-04 | UBS | Neutral | maintained | $81.93 | $85 | within 5% of price when set | +5.3% |
| 2026-06-04 | TD Cowen | Buy | reiterated | $81.93 | $119 | replaced 2026-07-10, new $100 | +5.3% |
| 2026-06-04 | RBC Capital | Outperform | reiterated | $81.93 | $118 | running to 2027-06-04 | +5.3% |
| 2026-06-04 | Wells Fargo | Overweight | maintained | $81.93 | $102 | replaced 2026-09-02, new $104 | +5.3% |
| 2026-06-04 | Leerink Partners | Outperform | maintained | $81.93 | $104 | running to 2027-06-04 | +5.3% |
| 2026-06-04 | Baird | Neutral | maintained | $81.93 | $85 | within 5% of price when set | +5.3% |
| 2026-06-04 | BTIG | Neutral → Buy | upgrade | $81.93 | $90 | reached 2026-08-11 | +5.3% |
| 2026-06-03 | Mizuho | Outperform | maintained | $77.95 | $100 | running to 2027-06-03 | -0.5% |
| 2026-06-03 | Needham | Buy | maintained | $77.95 | $101 | replaced 2026-08-27, new $114 | -0.5% |
| 2026-04-22 | UBS | Neutral | maintained | $83.22 | $90 | replaced 2026-06-04, new $85 | -4.5% |
| 2026-04-15 | Truist Securities | Hold | maintained | $87.10 | $95 | replaced 2026-09-02, new $99 | -1.3% |
| 2026-04-13 | Mizuho | Outperform | maintained | $88.00 | $120 | replaced 2026-06-03, new $100 | +1.0% |
| 2026-04-09 | Evercore ISI Group | Outperform | maintained | $87.91 | $106 | replaced 2026-07-06, new $105 | -2.2% |
| 2026-04-07 | Citigroup | Buy | maintained | $86.42 | $110 | running to 2027-04-07 | -4.9% |
| 2026-04-06 | Evercore ISI Group | Outperform | maintained | $86.28 | $108 | replaced 2026-04-09, new $106 | -5.1% |
| 2026-04-06 | Argus Research | Buy | maintained | $86.28 | $115 | running to 2027-04-06 | -5.1% |
| 2026-04-01 | Barclays | Overweight | maintained | $86.06 | $120 | replaced 2026-10-07, new $95 | -12.3% |
| 2026-04-01 | Piper Sandler | Neutral | maintained | $86.06 | $91 | reached 2026-08-14 | -12.3% |
| 2026-03-26 | Needham | Buy | reiterated | $87.67 | $120 | replaced 2026-06-03, new $101 | -9.4% |
| 2026-03-10 | Needham | Buy | reiterated | $89.89 | $120 | replaced 2026-06-03, new $101 | -12.6% |
| 2026-02-18 | JPMorgan | Neutral | maintained | $98.49 | $100 | within 5% of price when set | +1.8% |
| 2026-02-18 | Barclays | Overweight | maintained | $98.49 | $118 | replaced 2026-04-01, new $120 | +1.8% |
| 2026-02-18 | Baird | Neutral | maintained | $98.49 | $100 | within 5% of price when set | +1.8% |
| 2026-02-17 | Needham | Buy | maintained | $96.41 | $120 | replaced 2026-06-03, new $101 | -0.4% |
| 2026-02-09 | Needham | Hold → Buy | upgrade | $101.65 | $121 | replaced 2026-02-17, new $120 | +4.2% |
| 2026-02-04 | UBS | Neutral | maintained | $101.84 | $104 | within 5% of price when set | +4.6% |
| 2026-01-09 | Bernstein | Outperform | maintained | $97.53 | $112 | replaced 2026-06-05, new $97 | -3.2% |
| 2026-01-08 | Barclays | Overweight | maintained | $98.69 | $116 | replaced 2026-02-18, new $118 | -0.9% |
| 2026-01-06 | William Blair | Market Perform → Outperform | upgrade | $100.31 | — | no target | -1.0% |
| 2025-12-18 | Truist Securities | Hold | maintained | $98.48 | $107 | replaced 2026-04-15, new $95 | -2.3% |
| 2025-11-20 | Barclays | Overweight | maintained | $99.35 | $111 | replaced 2026-01-08, new $116 | — |
| 2025-11-20 | Truist Securities | Hold | maintained | $99.35 | $110 | replaced 2025-12-18, new $107 | — |
| 2025-11-19 | Morgan Stanley | Overweight | maintained | $100.34 | $117 | running to 2027-05-19 | — |
| 2025-11-19 | RBC Capital | Outperform | maintained | $100.34 | $118 | running to 2026-11-19 | — |
| 2025-11-19 | UBS | Neutral | maintained | $100.34 | $102 | within 5% of price when set | — |
| 2025-11-19 | Wells Fargo | Overweight | maintained | $100.34 | $114 | replaced 2026-06-04, new $102 | — |
| 2025-11-19 | Baird | Neutral | maintained | $100.34 | $109 | replaced 2026-02-18, new $100 | — |
| 2025-11-19 | Goldman Sachs | Sell → Neutral | upgrade | $100.34 | $111 | replaced 2026-06-05, new $83 | — |
| 2025-11-13 | JPMorgan | Neutral | maintained | $96.14 | $100 | within 5% of price when set | — |
Also in Medical Devices
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.